Inventor · disambiguated record
Dorthe Kot Engelund
Also filed as: ENGELUND DORTHE K · ENGELUND DORTHE KOT
8 granted patents·12 pending applications·152 citations·filing 2002–2024
89Inventor score
Files withNOVO NORDISK AS12PARSHAD HENRIK2PEDERSEN TINA BJELDSKOV2FLINK JAMES M1KNUDSEN LISELOTTE BJERRE1
Top patents by PatentIndex Score
20 records- 0191US8114833B2Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devicesPEDERSEN TINA BJELDSKOV·Filed 2006·Granted Feb 14, 2012·57 cites·31 claims
- 0291US7595293B2Stable pharmaceutical compositionsNOVO NORDISK AS·Filed 2005·Granted Sep 29, 2009·21 cites·52 claims
- 0390US8158583B2Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimiaKNUDSEN LISELOTTE BJERRE·Filed 2009·Granted Apr 17, 2012·18 cites·36 claims
- 0488US11318191B2GLP-1 compositions and uses thereofNOVO NORDISK AS·Filed 2021·Granted May 3, 2022·10 cites·26 claims
- 0586US8748376B2Stable formulations of peptidesLUDVIGSEN SVEND·Filed 2009·Granted Jun 10, 2014·21 cites·14 claims
- 0680US10835602B2Stable multi-dose compositions comprising an antibody and a preservativeNOVO NORDISK AS·Filed 2017·Granted Nov 17, 2020·1 cites·20 claims
- 0780US9795674B2Stable antibody containing compositionsPARSHAD HENRIK·Filed 2011·Granted Oct 24, 2017·15 cites·16 claims
- 0880US8846618B2Stable formulation of modified GLP-1FLINK JAMES M·Filed 2010·Granted Sep 30, 2014·9 cites·14 claims
- 0978US2023364241A1Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devicesNOVO NORDISK AS·Filed 2022·Application pending·0 cites
- 1070US2024415934A1Stable Semaglutide compositions and uses thereofNOVO NORDISK AS·Filed 2024·Application pending·0 cites
- 1167US2020316204A1Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devicesNOVO NORDISK AS·Filed 2020·Application pending·0 cites
- 1262US2009111752A1Stable Formulation of Modified GLP-1NOVO NORDISK AS·Filed 2008·Application pending·0 cites
- 1361US2019231876A1Propylene Glycol-Containing Peptide Formulations which are Optimal for Production and for Use in Injection DevicesNOVO NORDISK AS·Filed 2019·Application pending·0 cites
- 1459US2006287221A1Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimiaNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 1557US2008167226A1Stable formulation of modified GLP-1NOVO NORDISK AS·Filed 2007·Application pending·0 cites
- 1652US2012225810A1Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devicesPEDERSEN TINA BJELDSKOV·Filed 2012·Application pending·0 cites
- 1751US2021379159A1Stable semaglutide compositions and uses thereofNOVO NORDISK AS·Filed 2019·Application pending·0 cites
- 1847US2003119734A1Stable formulation of modified GLP-1Filed 2002·Application pending·0 cites
- 1942US2008125361A1Stable Formulations Of PeptidesNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 2039US2013136733A1Stable Multi-Dose Compositions Comprising an Antibody and a PreservativePARSHAD HENRIK·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →